Abstract
C-C chemokine receptor type 5 (CCR5) is known for its role as a co-receptor for HIV-1 infection. Some individuals possess a 32 bp deletion, known as Delta-32 allele which has been reported to confer resistance to HIV-1 infection. In order to estimate the distribution of Delta-32 allele of CCR5 gene, 1034 mestizo individuals from the Northwest of Mexico, including 385 HIV-1-infected individuals, 472 healthy controls and 177 uninfected female sex workers; were examined by allele-specific PCR. There was no statistically significant difference in the frequency of Delta-32 allele between HIV-1 positive and healthy individuals (OR= 1.1, p= 0.6). However, we found a significantly reduced prevalence of CCR5 Delta-32 heterozygous genotype in female patients (OR= 0.084, 95% CI= 0.011 - 0.630, p= 0.002), as well as in allele frequency, compared to male patients. Furthermore, we observed an inverse relationship between allele frequency and the risk of HIV-1 transmission and AIDS progression among female healthy controls, sex workers and HIV-1 infected groups. Our findings support previous data showing Delta-32 as a genetic protective factor against HIV-1 infection in Mexican women, as well as in women from other populations.
Keywords: AIDS, CCR5, delta-32, genetic marker, HIV-1, population genetics.
Current HIV Research
Title:Protective Effect of CCR5 Delta-32 Allele Against HIV-1 in Mexican Women
Volume: 11 Issue: 6
Author(s): JesUs A. Estrada-Aguirre, Silvestre G. Cazarez-Salazar, Luis A. Ochoa-Ramirez, Selene de J. Acosta-Cota, Roman Zamora-Gomez, Guilermi M. Najar-Reyes, Perla Villarreal-Escamilla, Ignacio Osuna-Ramirez, Sylvia P. Diaz-Camacho, Jorge G. Sanchez-Zazueta, Juan J. Rios-Tostado and Jesus S. Velarde-Felix
Affiliation:
Keywords: AIDS, CCR5, delta-32, genetic marker, HIV-1, population genetics.
Abstract: C-C chemokine receptor type 5 (CCR5) is known for its role as a co-receptor for HIV-1 infection. Some individuals possess a 32 bp deletion, known as Delta-32 allele which has been reported to confer resistance to HIV-1 infection. In order to estimate the distribution of Delta-32 allele of CCR5 gene, 1034 mestizo individuals from the Northwest of Mexico, including 385 HIV-1-infected individuals, 472 healthy controls and 177 uninfected female sex workers; were examined by allele-specific PCR. There was no statistically significant difference in the frequency of Delta-32 allele between HIV-1 positive and healthy individuals (OR= 1.1, p= 0.6). However, we found a significantly reduced prevalence of CCR5 Delta-32 heterozygous genotype in female patients (OR= 0.084, 95% CI= 0.011 - 0.630, p= 0.002), as well as in allele frequency, compared to male patients. Furthermore, we observed an inverse relationship between allele frequency and the risk of HIV-1 transmission and AIDS progression among female healthy controls, sex workers and HIV-1 infected groups. Our findings support previous data showing Delta-32 as a genetic protective factor against HIV-1 infection in Mexican women, as well as in women from other populations.
Export Options
About this article
Cite this article as:
Estrada-Aguirre A. JesUs, Cazarez-Salazar G. Silvestre, Ochoa-Ramirez A. Luis, Acosta-Cota de J. Selene, Zamora-Gomez Roman, Najar-Reyes M. Guilermi, Villarreal-Escamilla Perla, Osuna-Ramirez Ignacio, Diaz-Camacho P. Sylvia, Sanchez-Zazueta G. Jorge, Rios-Tostado J. Juan and Velarde-Felix S. Jesus, Protective Effect of CCR5 Delta-32 Allele Against HIV-1 in Mexican Women, Current HIV Research 2013; 11 (6) . https://dx.doi.org/10.2174/1570162X11666140101120225
DOI https://dx.doi.org/10.2174/1570162X11666140101120225 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis Diabetic Gastroenteropathy: Soothe the Symptoms or Unravel a Cure?
Current Diabetes Reviews Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Coupling of Conjugating Enzymes and Efflux Transporters: Impact on Bioavailability and Drug Interactions
Current Drug Metabolism Molecular and Genetic Bases of Pancreatic Cancer
Current Drug Targets Current Options for the Pharmacotherapy of Obesity
Current Pharmaceutical Design Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Contrast Enhanced Ultrasonography for Focal Liver Lesions Characterization: Clinical Perspective
Current Medical Imaging Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets Decreased lncRNA SNHG16 Accelerates Oxidative Stress Induced Pathological Angiogenesis in Human Retinal Microvascular Endothelial Cells by Regulating miR-195/mfn2 Axis
Current Pharmaceutical Design Diagnosis and Management of Lynch Syndrome
Recent Patents on Regenerative Medicine Carbonic Anhydrase Inhibitors and the Management of Cancer
Current Topics in Medicinal Chemistry Hepatobiliary Diseases and Insulin Resistance
Current Medicinal Chemistry Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design Proteomics of Human Pulmonary Surfactant Proteins
Current Proteomics Biomedical Applications of Carbon Nanotubes: A Critical Review
Current Drug Delivery Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings
Current Medicinal Chemistry Role of CCK/Gastrin Receptors in Gastrointestinal/Metabolic Diseases and Results of Human Studies Using Gastrin/CCK Receptor Agonists/Antagonists in these Diseases
Current Topics in Medicinal Chemistry microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design